Tenax Therapeutics Q2 2026 Earnings Report

Tenax Therapeutics EPS Results

• Actual EPS: N/A
• Consensus EPS: -$0.38
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Tenax Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Tenax Therapeutics Announcement Details

• Quarter: Q2 2026
• Date: 8/12/2026
• Time: Before Market Opens
• Conference Call Date: N/A
• Conference Call Time: N/A

Tenax Therapeutics (NASDAQ:TENX) is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions. The company conducts preclinical and clinical studies under the guidance of U.S. Food and Drug Administration regulations and is advancing its most advanced candidates toward pivotal trials.

Headquartered in Exton, Pennsylvania, Tenax Therapeutics serves hospitals, surgery centers and other healthcare facilities primarily in North America. The company collaborates with academic institutions and strategic partners to advance its pipeline. Tenax is managed by a team of executives with backgrounds in pharmaceutical development and commercialization, and it is publicly traded on the NASDAQ under the ticker symbol TENX.